Tags

Type your tag names separated by a space and hit enter

Influence of obesity on the antilipolytic effect of insulin in isolated human fat cells obtained before and after glucose ingestion.
J Clin Invest. 1984 Mar; 73(3):673-80.JCI

Abstract

The antilipolytic effect of insulin was studied in 9 obese and 10 age- and sex-matched subjects of normal weight. Isolated fat cells were taken before and 1 h after an 100 g oral glucose load. Insulin inhibition of basal and isoprenaline-induced rates of lipolysis were determined by using a sensitive bioluminescent glycerol assay. When compared with the controls, the obese group showed a lower glucose tolerance, a higher insulin secretion, and a lower specific insulin receptor binding per adipocyte surface area, which would suggest an insulin-resistant state. Before oral glucose, however, the sensitivity of the antilipolytic effect of insulin was enhanced 10-fold in obesity (P less than 0.01), but the maximum antilipolytic effect was not altered. Glucose ingestion induced a 10-25-fold increase in insulin sensitivity (P less than 0.01) and a 10% but not significant increase in specific adipocyte insulin receptor binding in the nonobese group. In the obese group, however, neither the insulin binding nor the antilipolytic effect of the hormone was increased by oral glucose. After oral glucose, insulin sensitivity was similar in the two groups. The concentration of the hormone which produced a half maximum effect was about 1 microU/ml. Similar results were obtained with insulin inhibition of basal and isoprenaline-stimulated glycerol release. It is concluded that, after an overnight fast, the sensitivity of the antilipolytic effect of insulin is markedly enhanced in adipocytes of "insulin-glucose resistant" obese subjects, presumably because of alterations at postreceptor levels of insulin action. In obesity, the antilipolytic effect of insulin seems normal after glucose ingestion. Furthermore, in adipocytes of subjects of normal weight, oral glucose rapidly stimulates the sensitivity of the antilipolytic effect of insulin, apparently because of changes at postreceptor sites. This short-term regulation of insulin action following the ingestion of glucose does not seem to be present in obesity.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6368586

Citation

Arner, P, et al. "Influence of Obesity On the Antilipolytic Effect of Insulin in Isolated Human Fat Cells Obtained Before and After Glucose Ingestion." The Journal of Clinical Investigation, vol. 73, no. 3, 1984, pp. 673-80.
Arner P, Bolinder J, Engfeldt P, et al. Influence of obesity on the antilipolytic effect of insulin in isolated human fat cells obtained before and after glucose ingestion. J Clin Invest. 1984;73(3):673-80.
Arner, P., Bolinder, J., Engfeldt, P., Hellmér, J., & Ostman, J. (1984). Influence of obesity on the antilipolytic effect of insulin in isolated human fat cells obtained before and after glucose ingestion. The Journal of Clinical Investigation, 73(3), 673-80.
Arner P, et al. Influence of Obesity On the Antilipolytic Effect of Insulin in Isolated Human Fat Cells Obtained Before and After Glucose Ingestion. J Clin Invest. 1984;73(3):673-80. PubMed PMID: 6368586.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of obesity on the antilipolytic effect of insulin in isolated human fat cells obtained before and after glucose ingestion. AU - Arner,P, AU - Bolinder,J, AU - Engfeldt,P, AU - Hellmér,J, AU - Ostman,J, PY - 1984/3/1/pubmed PY - 1984/3/1/medline PY - 1984/3/1/entrez SP - 673 EP - 80 JF - The Journal of clinical investigation JO - J Clin Invest VL - 73 IS - 3 N2 - The antilipolytic effect of insulin was studied in 9 obese and 10 age- and sex-matched subjects of normal weight. Isolated fat cells were taken before and 1 h after an 100 g oral glucose load. Insulin inhibition of basal and isoprenaline-induced rates of lipolysis were determined by using a sensitive bioluminescent glycerol assay. When compared with the controls, the obese group showed a lower glucose tolerance, a higher insulin secretion, and a lower specific insulin receptor binding per adipocyte surface area, which would suggest an insulin-resistant state. Before oral glucose, however, the sensitivity of the antilipolytic effect of insulin was enhanced 10-fold in obesity (P less than 0.01), but the maximum antilipolytic effect was not altered. Glucose ingestion induced a 10-25-fold increase in insulin sensitivity (P less than 0.01) and a 10% but not significant increase in specific adipocyte insulin receptor binding in the nonobese group. In the obese group, however, neither the insulin binding nor the antilipolytic effect of the hormone was increased by oral glucose. After oral glucose, insulin sensitivity was similar in the two groups. The concentration of the hormone which produced a half maximum effect was about 1 microU/ml. Similar results were obtained with insulin inhibition of basal and isoprenaline-stimulated glycerol release. It is concluded that, after an overnight fast, the sensitivity of the antilipolytic effect of insulin is markedly enhanced in adipocytes of "insulin-glucose resistant" obese subjects, presumably because of alterations at postreceptor levels of insulin action. In obesity, the antilipolytic effect of insulin seems normal after glucose ingestion. Furthermore, in adipocytes of subjects of normal weight, oral glucose rapidly stimulates the sensitivity of the antilipolytic effect of insulin, apparently because of changes at postreceptor sites. This short-term regulation of insulin action following the ingestion of glucose does not seem to be present in obesity. SN - 0021-9738 UR - https://www.unboundmedicine.com/medline/citation/6368586/Influence_of_obesity_on_the_antilipolytic_effect_of_insulin_in_isolated_human_fat_cells_obtained_before_and_after_glucose_ingestion_ L2 - https://doi.org/10.1172/JCI111259 DB - PRIME DP - Unbound Medicine ER -